Spectrum Dynamics Medical's VERITON-CT 400 All-Energy Unveiled Through Global Clinical Trials

Spectrum Dynamics Medical, a leader in digital SPECT and SPECT/CT technology, has made significant strides in nuclear medicine with the successful completion of initial clinical experiences using its enhanced VERITON-CT 400 All-Energy platform. This innovative system was tested at four renowned institutions worldwide, where it demonstrated impressive capabilities in both diagnostic and therapeutic imaging.

The clinical trials utilized a variety of radioactive isotopes including technetium-99m (Tc-99m), iodine-123 (I-123), lutetium-177 (Lu-177), iodine-131 (I-131), and actinium-225 (Ac-225). Each institution evaluated the system's performance in a range of applications tailored to their specific needs. The results collectively affirm that the VERITON-CT 400 All-Energy can deliver high-energy theranostic imaging without sacrificing the quality of diagnostic outputs.

Global Clinical Experience

The participating sites included promising institutions such as the Florida Theranostics in Jupiter, Florida, led by Dr. Ashok Muthu Krishnan; the Schneider Children's Medical Center in Israel, under Dr. Zvi Bar-Sever; the Huntsman Cancer Institute in Salt Lake City, Utah, with Dr. Jeff Yap at the helm; and the CHRU de Nancy in France, guided by Pr. Laetitia Imbert and Pr. Pierre-Yves Marie. Each institute adopted a unique approach in its evaluation of the VERITON-CT 400 AE, which focuses on increasing the versatility and efficiency of imaging processes in nuclear medicine.

The findings also indicate that the system can cater to various studies, as noted by Dr. Zvi Bar-Sever, who expressed satisfaction with the imaging capabilities across multiple Tc-99m based scans, including sentinel node lymphoscintigraphy and parathyroid imaging.

Technical Innovations

One of the critical advancements in this new platform is its digital CZT detection technology, designed for 360-degree geometry with a single-collimator architecture, which collectively magnifies imaging efficacy across different energy ranges. The system facilitates seamless transitions between low, medium, and high-energy isotopes, enabling comprehensive therapeutic planning, execution, and follow-up—all on a unified platform.

In response to the enhancement showcased by these institutions, Tomer Gabay, CEO of Spectrum Dynamics Medical, proudly announced, "The VERITON-CT 400 All-Energy is now the flagship of our portfolio and the clearest expression of where SPECT/CT is heading. Customers are already preparing orders in anticipation of our presentations at EANM."

Looking Ahead: EANM 2026

Spectrum Dynamics Medical plans to showcase its latest research and outcomes from the VERITON-CT 400 All-Energy during the EANM 2026 Annual Congress in Vienna, scheduled for October 17-21. Attendees will have an opportunity to view new clinical images, validation data, and phantom studies, emphasizing the platform's ability to facilitate advanced therapeutic imaging while maintaining high diagnostic efficacy.

Moreover, a lunch symposium titled "Driving Precision Nuclear Medicine with 360° CZT SPECT/CT" will be hosted, featuring discussions with experts in the field. This symposium will provide more in-depth insights into how the VERITON-CT platform can elevate nuclear medicine practices globally.

Conclusion

In summary, the VERITON-CT 400 All-Energy system marks a substantial leap forward in theranostics and imaging capabilities. Spectrum Dynamics Medical is well-positioned to lead the charge in revolutionizing nuclear medicine, ensuring clinicians are equipped with the best tools to deliver superior patient outcomes.

For additional insights and updates on Spectrum Dynamics and the VERITON platform, interested parties can visit their website.